Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, Gabriel Etienne, Amine Belhabri, Sarah Bertoli, Lauris Gastaud, Célestine Simand, Sylvain Chantepie, Madalina Uzunov, Alexis Genthon, Céline Berthon, Edmond Chiche, Pierre-Yves Dumas, Jacques Vargaftig, Géraldine Salmeron, Emilie Lemasle, Emmanuelle Tavernier, Jérémy Delage, Marion Loirat, Nadine Morineau, Félix Blanc-Durand, Patricia Pautier, Véronique Vergé, Nathalie Auger, Myrtille Thomas, Laetitia Stefani, Marion Lepelley, Thomas Boyer, Sylvain Thepot, Marie-Pierre Gourin, Pascal Bourquard, Matthieu Duchmann, Pierre-Marie Morice, Mauricette Michallet, Lionel Adès, Pierre Fenaux, Christian Récher, Hervé Dombret, Arnaud Pagès, Christophe Marzac, Alexandra Leary, Jean-Baptiste Micol
PURPOSE: To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). EXPERIMENTAL DESIGN: In a French cancer center, we identified and described the profiles of 13 t-MN diagnosed among 37 patients with ovarian cancer referred to hematology consultation for cytopenia under PARPi. Next, we described these 13 t-MN post-PARPi among 37 t-MN post ovarian cancer according to PARPi exposure. Finally, we described 69 t-MN post-PARPi in a national cohort...
December 1, 2022: Clinical Cancer Research